Which molecular-targeted agents are FDA-approved for treatment of renal cell carcinoma (RCC)?

Updated: Jun 08, 2020
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

The introduction of molecular-targeted therapy has essentially altered the management of advanced disease. Molecular-targeted agents approved by the US Food and Drug Administration (FDA) for treatment of metastatic kidney cancer include the following:

  • Sunitinib
  • Bevacizumab in combination with interferon
  • Pazopanib
  • Temsirolimus
  • Everolimus
  • Lenvatinib in combination with everolimus
  • Nivolumab (plus ipilimumab, for untreated poor-risk, advanced RCC)
  • Cabozantinib
  • Sorafenib
  • Axitinib

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!